1. Home
  2. BGLC vs PFSA Comparison

BGLC vs PFSA Comparison

Compare BGLC & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$3.05

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

PFSA

Profusa Inc.

N/A

Current Price

$0.10

Market Cap

8.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGLC
PFSA
Founded
2017
2009
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGLC
PFSA
Price
$3.05
$0.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
60.3M
Earning Date
11-14-2025
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,465,006.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.21
122.22
52 Week Low
$2.01
$0.07
52 Week High
$15.60
$12.76

Technical Indicators

Market Signals
Indicator
BGLC
PFSA
Relative Strength Index (RSI) 23.39 45.03
Support Level $3.02 $0.09
Resistance Level $3.52 $0.12
Average True Range (ATR) 0.22 0.02
MACD -0.06 0.00
Stochastic Oscillator 0.00 35.09

Price Performance

Historical Comparison
BGLC
PFSA

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: